US2023302111A1PendingUtilityA1

Immunogenic compositions comprising lawsonia intracellularis

82
Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INCPriority: Mar 14, 2005Filed: May 17, 2023Published: Sep 28, 2023
Est. expiryMar 14, 2025(expired)· nominal 20-yr term from priority
Inventors:Jeremy KrollMike Roof
A61P 31/00A61K 39/105A61K 39/0241A61K 39/0275A61K 39/12C12N 7/00A61K 35/74A61K 39/295A61K 39/39A61K 2039/521A61K 2039/522A61K 2039/525A61K 2039/542A61K 2039/55A61K 2039/552A61K 2039/55566A61K 2039/70C12N 2750/10034Y02A50/30Y10S424/825A61P 31/04A61P 31/10A61P 31/12A61K 39/116A61K 48/00
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method for the prophylaxis or treatment of diseases caused by  Lawsonia intracellularis , and one or more further swine pathogenic microorganism(s), wherein  Lawsonia intracellularis  bacterium antigen is administered to a non-human animal in need thereof together with at least two components of a further disease-causing organism for swine selected from the group consisting of:
 (i) killed  Lawsonia intracellularis  bacterium, 
 (ii) killed  Mycoplasma hyopneumoniae , and 
 (iii) Porcine circovirus. 
 
     
     
         2 . The method of  claim 1 , where components i., ii., and iii. May be administered as a pharmaceutical composition. 
     
     
         3 . The method of  claim 2 , wherein the pharmaceutical composition is administered in one dose. 
     
     
         4 . The method of  claim 3 , wherein the pharmaceutical composition is administered in multiple doses. 
     
     
         5 . The method of  claim 2 , wherein the first or single administration of said pharmaceutical composition is performed when the animal is about 2 to 3 weeks to about 8 weeks of age. 
     
     
         6 . The method of  claim 2 , wherein the second administration of said pharmaceutical composition is performed about 1 to 4 weeks after the first administration of said pharmaceutical composition. 
     
     
         7 . The method of  claim 2 , wherein an administration is performed in an interval of 3 to 12 months after administration of any previous pharmaceutical composition. 
     
     
         8 . The method of  claim 2 , wherein the amount of the pharmaceutical composition contains 10<2> to 10<9> TCID50 per dose. 
     
     
         9 . The method of  claim 2 , wherein the quantity of immunogen will be between 5 and 5000 micrograms. 
     
     
         10 . The method of  claim 2 , wherein the pharmaceutical composition further comprises a pharmaceutically-acceptable carrier. 
     
     
         11 . The method of  claim 10 , wherein the pharmaceutically-acceptable carrier is an adjuvant. 
     
     
         12 . The method of  claim 11 , wherein said adjuvant is selected from the group of water-in-oil emulsion, oil-in-water emulsion or water-in-oil-in-water emulsion. 
     
     
         13 . The method of  claim 1 , wherein said Porcine circovirus is the immunological active part.

Join the waitlist — get patent alerts

Track US2023302111A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.